Aurobindo Pharma Limited

rs,

(E), MUMBAI -400 051 To The Corporate Relations Department BSE LIMITED Phiroz Jeejeebhoy Towers, 25th floor, Dalal Street, MUMBAI -400 001 Company Code No. AUROPHARMA Company Code No. 524804

Rs 5,739.4 crore

f the quarter 5 Consolidated Financial & Business Highlights – Q2 FY23 Revenue from operations at Rs 5,739.4 crore, US revenues at US$ 331 Million Research & Development (R&D) spend at Rs 276 crore in Q2FY23, 4.8%

331 Million

al & Business Highlights – Q2 FY23 Revenue from operations at Rs 5,739.4 crore, US revenues at US$ 331 Million Research & Development (R&D) spend at Rs 276 crore in Q2FY23, 4.8% of revenue Vs. Rs. 310 crore in

Rs 276 crore

erations at Rs 5,739.4 crore, US revenues at US$ 331 Million Research & Development (R&D) spend at Rs 276 crore in Q2FY23, 4.8% of revenue Vs. Rs. 310 crore in Q1FY23, 5.0% of revenue EBIDTA before Forex and

4.8%

rore, US revenues at US$ 331 Million Research & Development (R&D) spend at Rs 276 crore in Q2FY23, 4.8% of revenue Vs. Rs. 310 crore in Q1FY23, 5.0% of revenue EBIDTA before Forex and Other income at

Rs. 310 crore

US$ 331 Million Research & Development (R&D) spend at Rs 276 crore in Q2FY23, 4.8% of revenue Vs. Rs. 310 crore in Q1FY23, 5.0% of revenue EBIDTA before Forex and Other income at Rs 836.9 crore; EBITDA margin

5.0%

& Development (R&D) spend at Rs 276 crore in Q2FY23, 4.8% of revenue Vs. Rs. 310 crore in Q1FY23, 5.0% of revenue EBIDTA before Forex and Other income at Rs 836.9 crore; EBITDA margin is at 14.6% Ne

Rs 836.9 crore

of revenue Vs. Rs. 310 crore in Q1FY23, 5.0% of revenue EBIDTA before Forex and Other income at Rs 836.9 crore; EBITDA margin is at 14.6% Net Profit at Rs 409.4 crore Basic & Diluted EPS is Rs 6.99 per share

14.6%

Y23, 5.0% of revenue EBIDTA before Forex and Other income at Rs 836.9 crore; EBITDA margin is at 14.6% Net Profit at Rs 409.4 crore Basic & Diluted EPS is Rs 6.99 per share Net organic capex for the

Rs 409.4 crore

EBIDTA before Forex and Other income at Rs 836.9 crore; EBITDA margin is at 14.6% Net Profit at Rs 409.4 crore Basic & Diluted EPS is Rs 6.99 per share Net organic capex for the quarter ~US$ 81 Million includ

Rs 6.99

at Rs 836.9 crore; EBITDA margin is at 14.6% Net Profit at Rs 409.4 crore Basic & Diluted EPS is Rs 6.99 per share Net organic capex for the quarter ~US$ 81 Million including investment of ~US$ 31 Million

81 Million

at Rs 409.4 crore Basic & Diluted EPS is Rs 6.99 per share Net organic capex for the quarter ~US$ 81 Million including investment of ~US$ 31 Million in PLI I project Net cash including investments at the en